2025-01-012025-12-312025-12-31false04610479THE OCTAGON CLINIC LIMITED2026-05-1986900falseiso4217:GBPxbrli:pure046104792024-12-31046104792025-12-31046104792025-01-012025-12-31046104792023-12-31046104792024-12-31046104792024-01-012024-12-3104610479bus:SmallEntities2025-01-012025-12-3104610479bus:AuditExempt-NoAccountantsReport2025-01-012025-12-3104610479bus:FullAccounts2025-01-012025-12-3104610479bus:PrivateLimitedCompanyLtd2025-01-012025-12-3104610479core:WithinOneYear2025-12-3104610479core:AfterOneYear2025-12-3104610479core:WithinOneYear2024-12-3104610479core:AfterOneYear2024-12-3104610479core:ShareCapital2025-12-3104610479core:SharePremium2025-12-3104610479core:RevaluationReserve2025-12-3104610479core:OtherReservesSubtotal2025-12-3104610479core:RetainedEarningsAccumulatedLosses2025-12-3104610479core:ShareCapital2024-12-3104610479core:SharePremium2024-12-3104610479core:RevaluationReserve2024-12-3104610479core:OtherReservesSubtotal2024-12-3104610479core:RetainedEarningsAccumulatedLosses2024-12-3104610479core:LandBuildings2025-12-3104610479core:PlantMachinery2025-12-3104610479core:Vehicles2025-12-3104610479core:FurnitureFittings2025-12-3104610479core:OfficeEquipment2025-12-3104610479core:NetGoodwill2025-12-3104610479core:IntangibleAssetsOtherThanGoodwill2025-12-3104610479core:ListedExchangeTraded2025-12-3104610479core:UnlistedNon-exchangeTraded2025-12-3104610479core:LandBuildings2024-12-3104610479core:PlantMachinery2024-12-3104610479core:Vehicles2024-12-3104610479core:FurnitureFittings2024-12-3104610479core:OfficeEquipment2024-12-3104610479core:NetGoodwill2024-12-3104610479core:IntangibleAssetsOtherThanGoodwill2024-12-3104610479core:ListedExchangeTraded2024-12-3104610479core:UnlistedNon-exchangeTraded2024-12-3104610479core:LandBuildings2025-01-012025-12-3104610479core:PlantMachinery2025-01-012025-12-3104610479core:Vehicles2025-01-012025-12-3104610479core:FurnitureFittings2025-01-012025-12-3104610479core:OfficeEquipment2025-01-012025-12-3104610479core:NetGoodwill2025-01-012025-12-3104610479core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3104610479core:ListedExchangeTraded2025-01-012025-12-3104610479core:UnlistedNon-exchangeTraded2025-01-012025-12-3104610479core:MoreThanFiveYears2025-01-012025-12-3104610479core:Non-currentFinancialInstruments2025-12-3104610479core:Non-currentFinancialInstruments2024-12-3104610479dpl:CostSales2025-01-012025-12-3104610479dpl:DistributionCosts2025-01-012025-12-3104610479core:LandBuildings2025-01-012025-12-3104610479core:PlantMachinery2025-01-012025-12-3104610479core:Vehicles2025-01-012025-12-3104610479core:FurnitureFittings2025-01-012025-12-3104610479core:OfficeEquipment2025-01-012025-12-3104610479dpl:AdministrativeExpenses2025-01-012025-12-3104610479core:NetGoodwill2025-01-012025-12-3104610479core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3104610479dpl:GroupUndertakings2025-01-012025-12-3104610479dpl:ParticipatingInterests2025-01-012025-12-3104610479dpl:GroupUndertakingscore:ListedExchangeTraded2025-01-012025-12-3104610479core:ListedExchangeTraded2025-01-012025-12-3104610479dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-01-012025-12-3104610479core:UnlistedNon-exchangeTraded2025-01-012025-12-3104610479dpl:CostSales2024-01-012024-12-3104610479dpl:DistributionCosts2024-01-012024-12-3104610479core:LandBuildings2024-01-012024-12-3104610479core:PlantMachinery2024-01-012024-12-3104610479core:Vehicles2024-01-012024-12-3104610479core:FurnitureFittings2024-01-012024-12-3104610479core:OfficeEquipment2024-01-012024-12-3104610479dpl:AdministrativeExpenses2024-01-012024-12-3104610479core:NetGoodwill2024-01-012024-12-3104610479core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3104610479dpl:GroupUndertakings2024-01-012024-12-3104610479dpl:ParticipatingInterests2024-01-012024-12-3104610479dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-012024-12-3104610479core:ListedExchangeTraded2024-01-012024-12-3104610479dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-012024-12-3104610479core:UnlistedNon-exchangeTraded2024-01-012024-12-3104610479core:NetGoodwill2025-12-3104610479core:IntangibleAssetsOtherThanGoodwill2025-12-3104610479core:LandBuildings2025-12-3104610479core:PlantMachinery2025-12-3104610479core:Vehicles2025-12-3104610479core:FurnitureFittings2025-12-3104610479core:OfficeEquipment2025-12-3104610479core:AfterOneYear2025-12-3104610479core:WithinOneYear2025-12-3104610479core:ListedExchangeTraded2025-12-3104610479core:UnlistedNon-exchangeTraded2025-12-3104610479core:ShareCapital2025-12-3104610479core:SharePremium2025-12-3104610479core:RevaluationReserve2025-12-3104610479core:OtherReservesSubtotal2025-12-3104610479core:RetainedEarningsAccumulatedLosses2025-12-3104610479core:NetGoodwill2024-12-3104610479core:IntangibleAssetsOtherThanGoodwill2024-12-3104610479core:LandBuildings2024-12-3104610479core:PlantMachinery2024-12-3104610479core:Vehicles2024-12-3104610479core:FurnitureFittings2024-12-3104610479core:OfficeEquipment2024-12-3104610479core:AfterOneYear2024-12-3104610479core:WithinOneYear2024-12-3104610479core:ListedExchangeTraded2024-12-3104610479core:UnlistedNon-exchangeTraded2024-12-3104610479core:ShareCapital2024-12-3104610479core:SharePremium2024-12-3104610479core:RevaluationReserve2024-12-3104610479core:OtherReservesSubtotal2024-12-3104610479core:RetainedEarningsAccumulatedLosses2024-12-3104610479core:NetGoodwill2023-12-3104610479core:IntangibleAssetsOtherThanGoodwill2023-12-3104610479core:LandBuildings2023-12-3104610479core:PlantMachinery2023-12-3104610479core:Vehicles2023-12-3104610479core:FurnitureFittings2023-12-3104610479core:OfficeEquipment2023-12-3104610479core:AfterOneYear2023-12-3104610479core:WithinOneYear2023-12-3104610479core:ListedExchangeTraded2023-12-3104610479core:UnlistedNon-exchangeTraded2023-12-3104610479core:ShareCapital2023-12-3104610479core:SharePremium2023-12-3104610479core:RevaluationReserve2023-12-3104610479core:OtherReservesSubtotal2023-12-3104610479core:RetainedEarningsAccumulatedLosses2023-12-3104610479core:AfterOneYear2025-01-012025-12-3104610479core:WithinOneYear2025-01-012025-12-3104610479core:Non-currentFinancialInstrumentscore:CostValuation2025-01-012025-12-3104610479core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-012025-12-3104610479core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-012025-12-3104610479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-012025-12-3104610479core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-012025-12-3104610479core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-012025-12-3104610479core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3104610479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3104610479core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3104610479core:Non-currentFinancialInstrumentscore:CostValuation2025-12-3104610479core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-12-3104610479core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-12-3104610479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-12-3104610479core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-12-3104610479core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-12-3104610479core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-12-3104610479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-12-3104610479core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-12-3104610479core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3104610479core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3104610479core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3104610479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3104610479core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3104610479core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3104610479core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3104610479core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3104610479core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3104610479bus:Director12025-01-012025-12-3104610479core:FurnitureFittingsToolsEquipment2024-12-3104610479core:FurnitureFittingsToolsEquipment2025-01-012025-12-3104610479core:FurnitureFittingsToolsEquipment2025-12-31

THE OCTAGON CLINIC LIMITED

Registered Number
04610479
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2025

THE OCTAGON CLINIC LIMITED
Company Information
for the year from 1 January 2025 to 31 December 2025

Director

Dr T Tellefsen Hughes

Company Secretary

Dr T Tellefsen Hughes

Registered Address

10 Cheyne Walk
Northampton
NN1 5PT

Registered Number

04610479 (England and Wales)
THE OCTAGON CLINIC LIMITED
Balance Sheet as at
31 December 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets441,7553,430
41,7553,430
Current assets
Stocks5300344
Debtors615,12718,093
Cash at bank and on hand100,700222,405
116,127240,842
Creditors amounts falling due within one year7(49,003)(52,929)
Net current assets (liabilities)67,124187,913
Total assets less current liabilities108,879191,343
Net assets108,879191,343
Capital and reserves
Called up share capital11
Profit and loss account108,878191,342
Shareholders' funds108,879191,343
The financial statements were approved and authorised for issue by the Director on 19 May 2026, and are signed on its behalf by:
Dr T Tellefsen Hughes
Director
Registered Company No. 04610479
THE OCTAGON CLINIC LIMITED
Notes to the Financial Statements
for the year ended 31 December 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime). Summary of significant accounting policies and key accounting estimates The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
Judgements and key sources of estimation uncertainty
In applying the Company's accounting policies, the directors are required to make judgements, estimates and assumptions in determining the carrying amounts of assets and liabilities. The directors' best judgements, estimates and assumptions are based on the best and most reliable evidence available at the time when the decisions are made, and are based on historical experience and other factors that are considered to be appropriate. Due to the inherent subjectivity involved in making such judgements, estimates and assumptions, the actual results and outcomes may differ. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.
Revenue from sale of goods
Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts. The company recognises revenue when: The amount of revenue can be reliably measured; it is probable that future economic benefits will flow to the entity; and specific criteria have been met for each of the company's activities.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Defined contribution pension plan
A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.
Deferred tax
Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements. Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Amortisation
Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows: Asset class Goodwill - No amortisation charged
Goodwill
Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.
Tangible fixed assets and depreciation
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses. The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation. Depreciation Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Straight line (years)
Land and buildings5
Fixtures and fittings6.67
Office Equipment5
Stocks and work in progress
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method. The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.
Trade and other debtors
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.
Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.
Trade and other creditors
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities. Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.
Financial instruments
Classification The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, loans from banks and other third parties and loans to related parties. Debt instruments such as loans and other accounts receivable and payable are initially measured at present value of the future payments and subsequently at amortised cost using the effective interest method; Debt instruments that are payable or receivable within one year, typically trade payables or receivables, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However if the arrangements of a short-term instrument constitute a financing transaction, such as the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in the case of an outright short-term loan not at market rate, the financial asset or liability is measured, initially and subsequently, at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in profit or loss. Financial assets and liabilities are offset and the net amount reported in the statement of financial position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Loss/profit before tax Arrived at after charging/(crediting) Depreciation expense £4,510 (2024 - £1,793)
2.Average number of employees

20252024
Average number of employees during the year33
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 January 25150,000150,000
At 31 December 25150,000150,000
Amortisation and impairment
At 01 January 25150,000150,000
At 31 December 25150,000150,000
Net book value
At 31 December 25--
At 31 December 24--
4.Tangible fixed assets

Land & buildings

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 January 25118,61529,222900148,737
Additions30,45011,2851,10042,835
Disposals-(5,712)-(5,712)
At 31 December 25149,06534,7952,000185,860
Depreciation and impairment
At 01 January 25118,61525,792900145,307
Charge for year2,3481,9971654,510
On disposals-(5,712)-(5,712)
At 31 December 25120,96322,0771,065144,105
Net book value
At 31 December 2528,10212,71893541,755
At 31 December 24-3,430-3,430
5.Stocks

2025

2024

££
Other stocks300344
Total300344
6.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables8001,742
Other debtors-15,637
Prepayments and accrued income14,327714
Total15,12718,093
7.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables1,03010,868
Bank borrowings and overdrafts142129
Taxation and social security5,654-
Other creditors32,65923,359
Accrued liabilities and deferred income9,51818,573
Total49,00352,929
8.Provisions for liabilities
9.Share capital
Allotted, called up and fully paid shares 1 Ordinary share of £1 each 9. Dividends Interim dividend of £Nil (2024 - £37,525.00) per ordinary share